Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Thirty-day mortality was dramatically reduced by the administration of aspirin (ASA) during the hospitalization. The p value for each mortality comparison between patients taking ASA and those not receiving ASA was <0.001. The relative risk reduction in mortality was significantly greater for patients without end-stage renal disease (ESRD) than for those with ESRD in the entire cohort (63% vs. 50%, p = 0.01). After restricting the cohort to patients ideal for ASA, the reduction in mortality provided by aspirin therapy remained greater in the non-ESRD group, although it was no longer statistically significant (65% vs. 53%, p = 0.10).
|
